Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Mendes Ferreira (Porto, Portugal), B. Tielemans (Leuven, Belgium), A. Wagenaar (Leuven, Belgium), C. Dessy (Brussels, Belgium), J. Balligand (Brussels, Belgium), M. Delcroix (Leuven, Belgium), R. Quarck (Leuven, Belgium), C. Belge (Leuven, Belgium). Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension. 1490

Member's Comments

No comment yet.

Related content which might interest you: Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Phosphodiesterase 1 upregulation in pulmonary arterial hypertension – target for anti-remodeling therapy Source: Eur Respir J 2006; 28: Suppl. 50, 159s Year: 2006 Novel therapeutic perspectives in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 193-194 Year: 2003 Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019 Year: 2021 The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1702638; 10.1183/13993003.02638-2017 Year: 2018 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011 ?-blockers in pulmonary arterial hypertension: generation might matter Source: Eur Respir J 2016; 47: 682-684 Year: 2016 Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment? Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Expression of the serotonin 1b receptor in experimental pulmonary hypertension Source: Eur Respir J 2003; 22: 408-412 Year: 2003 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011